MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trincavelli, M. L.
Right arrow Articles by Martini, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trincavelli, M. L.
Right arrow Articles by Martini, C.

Vol. 62, Issue 6, 1373-1384, December 2002

A3 Adenosine Receptors in Human Astrocytoma Cells: Agonist-Mediated Desensitization, Internalization, and Down-Regulation

M. L. Trincavelli, D. Tuscano, M. Marroni, A. Falleni, V. Gremigni, S. Ceruti, M. P. Abbracchio, K. A. Jacobson, F. Cattabeni, and C. Martini

Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Universitá Pisa, Pisa, Italy (M.L.T., D.T., M.M., C.M.); Dipartimento di Morfologia Umana e Biologia Applicata, Universitá Pisa, Pisa, Italy (A.F., V.G.); Dipartimento di Scienze Farmacologiche, Universitá Milano, Milan, Italy (S.C., M.P.A., F.C.); and Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (K.A.J.)

A3 adenosine receptor activation has been previously demonstrated to result in both neuroprotective and neurodegenerative effects, depending upon specific pathophysiological conditions. This dual effect may depend on receptor regulation mechanisms that are able to change receptor availability and/or function. In the present study, we investigated desensitization, internalization, and down-regulation of native A3 adenosine receptors in human astrocytoma cells after exposure to the agonist 2-chloro-N6-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine (Cl-IBMECA). Cl-IBMECA induced a concentration-dependent inhibition of adenylyl cyclase activity with an EC50 value of 2.9 ± 0.1 nM. The effect was suggested to be mediated by A3 adenosine receptor subtype by the use of selective adenosine receptor antagonists. Cell treatment with pertussis toxin abolished Cl-IBMECA-mediated inhibition of adenylyl cyclase activity, evidencing an A3 receptor coupling to inhibitory G protein. Short-term exposure to the agonist Cl-IBMECA (100 nM) caused rapid receptor desensitization, within 15 min. Agonist-induced desensitization was accompanied by receptor internalization: A3 adenosine receptor internalized with rapid kinetics, within 30 min, after cell exposure to 100 nM Cl-IBMECA. The localization of A3 adenosine receptors on the plasma membrane and in intracellular compartments was directly revealed by immunogold electron microscopy. After desensitization, the removal of agonist led to the restoration of A3 adenosine receptor functioning through receptor recycling to the cell surface within 120 min. Prolonged agonist exposure (1-24 h) resulted in a marked down-regulation of A3 adenosine receptors that reached 21.9 ± 2.88% of control value after 24 h. After down-regulation, the recovery of receptor functioning was slow (24 h) and associated with the restoration of receptor levels close to control values. In conclusion, our results demonstrated that A3 receptors, in astrocytoma cells, are regulated after short- and long-term agonist exposure.


Copyright © 2002 by U.S. Government



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
B. Costa, A. Salvetti, L. Rossi, F. Spinetti, A. Lena, B. Chelli, M. Rechichi, E. Da Pozzo, V. Gremigni, and C. Martini
Peripheral Benzodiazepine Receptor: Characterization in Human T-Lymphoma Jurkat Cells
Mol. Pharmacol., January 1, 2006; 69(1): 37 - 44.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Madi, A. Ochaion, L. Rath-Wolfson, S. Bar-Yehuda, A. Erlanger, G. Ohana, A. Harish, O. Merimski, F. Barer, and P. Fishman
The A3 Adenosine Receptor Is Highly Expressed in Tumor versus Normal Cells: Potential Target for Tumor Growth Inhibition
Clin. Cancer Res., July 1, 2004; 10(13): 4472 - 4479.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Madi, S. Bar-Yehuda, F. Barer, E. Ardon, A. Ochaion, and P. Fishman
A3 Adenosine Receptor Activation in Melanoma Cells: ASSOCIATION BETWEEN RECEPTOR FATE AND TUMOR GROWTH INHIBITION
J. Biol. Chem., October 24, 2003; 278(43): 42121 - 42130.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics